SCHEMBL4674028

SCHEMBL4674028

O=C(O)C(O)=CC(=O)c1cc(Cc2ccccc2)cs1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 2/20 0.49
MAPT P10636 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
LTB4R Q15722 1/20 0.38
GPR52 Q9Y2T5 1/20 0.37
PLA2G10 O15496 1/20 0.36
PLA2G2A P14555 1/20 0.36
LMNA P02545 1/20 0.36
HNF4A P41235 1/20 0.36
POLB P06746 1/20 0.35
HPGD P15428 1/20 0.35
CALM1 P0DP23 1/20 0.35
PTPN1 P18031 2/20 0.34
HDAC6 Q9UBN7 2/20 0.34
PTPN2 P17706 1/20 0.34
PTPN6 P29350 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
IDH1 O75874 1/20 0.33
MMP12 P39900 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4674025 1.00 DAO (0.49) DAOMAPTNPSR1LTB4RGPR52
SCHEMBL4674875 0.87 MAPT (0.43) DAOMAPTNPSR1LMNAHPGD
SCHEMBL4673052 0.87 MAPT (0.46) DAOMAPTNPSR1LMNAPOLB
SCHEMBL4674872 0.87 MAPT (0.43) DAOMAPTNPSR1LMNAHPGD
SCHEMBL4675253 0.87 MAPT (0.43) DAOMAPTNPSR1PLA2G10PLA2G2A
SCHEMBL4673797 0.87 MAPT (0.43) DAOMAPTNPSR1HDAC6HDAC1
SCHEMBL4673048 0.87 MAPT (0.46) DAOMAPTNPSR1LMNAPOLB
SCHEMBL4675249 0.87 MAPT (0.43) DAOMAPTNPSR1PLA2G10PLA2G2A
SCHEMBL4673801 0.87 MAPT (0.43) DAOMAPTNPSR1HDAC6HDAC1
SCHEMBL4676593 0.87 MAPT (0.40) DAOMAPTNPSR1GPR52LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 DAO 661/4885MAPT 205/4885NPSR1 937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.